Clinical Trials
54 trialsT-DIS
Centre Oscar Lambret
PIPER
Institut BergoniƩ
TRABEPIO
Mario Negri Institute for Pharmacological Research
U01CA236220
Sarcoma Alliance for Research through Collaboration
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Trabectedin for Recurrent Grade II/III Meningioma
European Organisation for Research and Treatment of Cancer - EORTC
STRADA
Italian Sarcoma Group
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
YonSar
PharmaMar, Spain
Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
NiTraSarc
University Medicine Greifswald
INOVATYON
Mario Negri Institute for Pharmacological Research
TRAVELL
Italian Sarcoma Group
NIMES-ROC
PharmaMar
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
MITO 26
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
TOMAS
Italian Sarcoma Group
Metabol-STS
Centro di Riferimento Oncologico - Aviano
RETRO-ROC
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
ATREUS
Mario Negri Institute for Pharmacological Research
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Mario Negri Institute for Pharmacological Research
TrObs
Italian Sarcoma Group
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Children's Oncology Group
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
TR1US
Italian Sarcoma Group
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
TAUL
Mario Negri Institute for Pharmacological Research
Tabectedin to Treat Children and Adolescents With Cancer
National Institutes of Health Clinical Center (CC)
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Janssen Research & Development, LLC
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
Janssen Research & Development, LLC
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
Janssen Research & Development, LLC
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Heidelberg University
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PACT-18
IRCCS San Raffaele
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Massachusetts General Hospital
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.